Who are Lenalidomide/Low dose Dex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Drug: Carfilzomib + Lenalidomide + Dexamethasone, VRD for first-cycle induction therapy, Carfilzomib Lenalidomide Dexamethasone, Lenalidomide and Dexamethasone, Bortezomib/Lenalidomide/ Low dose Dex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lenalidomide-low-dose-dex.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Lenalidomide/Low dose Dex — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lenalidomide/Low dose Dex (Lenalidomide/Low dose Dex) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulatory agent + corticosteroid combination. Area: Oncology.

phase 3 Immunomodulatory agent + corticosteroid combination Cereblon (CRBN), TNF-α pathway, glucocorticoid receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Lenalidomide/Low dose Dex (Lenalidomide/Low dose Dex) — King Faisal Specialist Hospital & Research Center. Lenalidomide enhances immune cell proliferation and anti-tumor activity while dexamethasone provides anti-inflammatory and anti-myeloma effects.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lenalidomide/Low dose Dex TARGET	Lenalidomide/Low dose Dex	King Faisal Specialist Hospital & Research Center	phase 3	Immunomodulatory agent + corticosteroid combination	Cereblon (CRBN), TNF-α pathway, glucocorticoid receptor
Drug: Carfilzomib + Lenalidomide + Dexamethasone	Drug: Carfilzomib + Lenalidomide + Dexamethasone	Amgen	marketed	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	20S proteasome (carfilzomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
VRD for first-cycle induction therapy	VRD for first-cycle induction therapy	The First Affiliated Hospital of Soochow University	marketed	Proteasome inhibitor + immunomodulatory agent + corticosteroid combination	26S proteasome (bortezomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
Carfilzomib Lenalidomide Dexamethasone	Carfilzomib Lenalidomide Dexamethasone	European Myeloma Network B.V.	phase 3	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	20S proteasome (carfilzomib); Cereblon/E3 ubiquitin ligase (lenalidomide); Glucocorticoid receptor (dexamethasone)
Lenalidomide and Dexamethasone	Lenalidomide and Dexamethasone	HuniLife Biotechnology, Inc.	phase 3	Immunomodulatory agent + corticosteroid combination	Cereblon (CRBN), TNF-α pathway; glucocorticoid receptor
Bortezomib/Lenalidomide/ Low dose Dex	Bortezomib/Lenalidomide/ Low dose Dex	King Faisal Specialist Hospital & Research Center	phase 3	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	Proteasome (bortezomib); Cereblon (lenalidomide); Glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulatory agent + corticosteroid combination class)

HuniLife Biotechnology, Inc. · 1 drug in this class
King Faisal Specialist Hospital & Research Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lenalidomide/Low dose Dex — Competitive Intelligence Brief. https://druglandscape.com/ci/lenalidomide-low-dose-dex. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing